ArticleScientific reports2025

Cost-effectiveness of finotonlimab plus chemotherapy versus chemotherapy alone for recurrent or metastatic head and neck cancer in China.

Yu Zeng et al.PubMed ↗Full text ↗Publisher ↗

No numbers read from the abstract.